source
- Sanofi halts development of Kymab-derived OX40L antibody for atopic dermatitisSanofi announced that it will no longer pursue the OX40L antibody program it was developing with Kymab for the treatment of atopic dermatitis. The drug was being positioned as a potential follow‑on…
- Novo Nordisk seeks court order to halt Lilly GLP-1 ads as Merck announces HIV PrEP partnershipNovo Nordisk asked a New Jersey federal court to temporarily block Eli Lilly's GLP-1 advertisements, claiming the ads are misleading. Merck disclosed that it has entered into a partnership focused…